Hong Kong stocks surge: Canbridge Jerai Pharmaceuticals-B (09966.HK) up over 6%. Enitou reaches primary endpoint in Phase III clinical trial for first-line treatment of HER2-positive advanced breast cancer.

According to the Wisdom Financial App, Kunjing Jeri Pharmaceutical-B (09966.HK) surged over 6%, as of the time of release, it rose 4.22% to 6.92 Hong Kong dollars, with a turnover of 5.1534 million Hong Kong dollars.